Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival

Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.